Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• De Vorkin L, Hattersley M, Kim P, et al. Autophagy inhibition enhances sunitinib efficacy in clear cell ovarian carcinoma. Mol Cancer Res. 2017;15(3):250–258. doi:10.1158/1541-7786.MCR-16-0132
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, De Santis CE, et al. Ovarian cancer statistics, 2018. CA CANCER J CLIN. 2018;68:284–296. doi:10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Wang YX, Wang YX, Li YK, et al. The emerging roles of extracellular vesicles in ovarian cancer. Curr Drug Metab. 2021;22(2):139–149. doi:10.2174/1389200221666201110155721
   PubMed Web of Science ®Google Scholar
• Akinwunmi BO, Babic A, Vitonis AF, et al. Chronic medical conditions and CA125 levels among women without ovarian cancer. Cancer Epidemiol Prev Biomarkers. 2018;27(12):1483–1490. doi:10.1158/1055-9965.EPI-18-0203
   PubMed Web of Science ®Google Scholar
• Feng F, Tian Y, Xu G, et al. Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017;17(1):1–6. doi:10.1186/s12885-017-3738-y
   PubMed Web of Science ®Google Scholar
• Fan HY, Duan DM, Liu YF. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19. 9 in patients with ovarian cancer. Eur Rev Med Pharmacol Sci. 2017;21(18):4039–4044.
   PubMed Web of Science ®Google Scholar
• Peng SJ, Wang CF, Yu YJ, et al. CYFRA21-1/TG ratio as an accurate risk factor to predict eye metastasis in nasopharyngeal carcinoma: a STROBE-compliant article. Medicine. 2020;99:46. doi:10.1097/MD.0000000000022773
   Web of Science ®Google Scholar
• Stall KE, Martin EW Jr. Plasma carcinoembryonic antigen levels in ovarian cancer patients: a chart review and survey of published data. J Reprod Med. 1981;26(2):73–79.
   PubMed Web of Science ®Google Scholar
• Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000;11(2):111–117. doi:10.1097/00001648-200003000-00006
   PubMed Web of Science ®Google Scholar
• Abu-Shawer O, Abu-Shawer M, Haimour A, et al. Hematologic markers of distant metastases in gastric cancer. J Gastrointest Oncol. 2019;10(3):529. doi:10.21037/jgo.2019.01.12
   PubMed Web of Science ®Google Scholar
• Mezouar S, Frère C, Darbousset R, et al. Role of platelets in cancer and cancer-associated thrombosis: experimental and clinical evidences. Thromb Res. 2016;139:65–76. doi:10.1016/j.thromres.2016.01.006
   PubMed Web of Science ®Google Scholar
• Lammert J, Skandarajah AR, Shackleton K, et al. Outcomes of women at high familial risk for breast cancer: an 8-year single-center experience. Asia Pac J Clin Oncol. 2020;16(2):27–37.
   Web of Science ®Google Scholar
• Morse CB, Norquist BM, Harrell MI, et al. Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016;143(2):389–392. doi:10.1016/j.ygyno.2016.08.324
   PubMed Web of Science ®Google Scholar
• Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28. doi:10.1186/s13048-019-0503-7
   PubMed Web of Science ®Google Scholar
• Drapkin R, Von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotei n that is overexpressed by serous and endometrioid ovarian carci nomas. Cancer Res. 2005;65(6):2162–2169. doi:10.1158/0008-5472.CAN-04-3924
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110(3):374–382. doi:10.1016/j.ygyno.2008.04.041
   PubMed Web of Science ®Google Scholar
• Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Ghaffar HMA. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol. 2013;8(1):11–18. doi:10.1186/1746-1596-8-11
   PubMed Web of Science ®Google Scholar
• Rasmussen CB, Kjaer SK, Albieri V, et al. Pelvic information disease and the risk of ovarian cancer and borderline ovarian tumor: a pooled analysis of 13 case-control studies. Am J Epidemiol. 2017;185(1):8–20. doi:10.1093/aje/kww161
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71(7):2411–2416. doi:10.1158/0008-5472.CAN-10-2583
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi:10.1002/cncr.30057
   PubMed Web of Science ®Google Scholar
• Yang B. The Clinical Significance of Preoperative LMR and PNI in the Diagnosis of Ovarian Malignant Tumors [D]. Yanbian University; 2019.
   Google Scholar
• Jenne CN, Kubes P. Platelets in inflammation and infection. Platelets. 2015;26(4):286. doi:10.3109/09537104.2015.1010441
   PubMed Web of Science ®Google Scholar
• Davis A, Afsharkharghan V, Sood AK. Platelet effects on ovarian cancer. Semin Oncol. 2014;41(3):378–384. doi:10.1053/j.seminoncol.2014.04.004
   PubMed Web of Science ®Google Scholar
• Li QQ, Lu ZH, Yang L, et al. Neutrophil count and the inflammation-based Glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev. 2014;15(2):945–950. doi:10.7314/APJCP.2014.15.2.945
   PubMedGoogle Scholar
• Shen J, Zhu Y, Wu W, et al. Prognostic role of neutrophil-to-lymphocyte ratio in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Med Sci Monit. 2017;23:315–324.
   PubMed Web of Science ®Google Scholar
• Yildiz Y, Kucukzeybek Y, Alacacioglu A, et al. Prognostic value of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with epithelial ovarian cancer. Eur Gynaecol Oncol. 2017;38(3):444–448.
   Google Scholar
• Miao Y, Yan Q, Li S, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. Cancer Biomarkers. 2016;17(1):33–40. doi:10.3233/CBM-160614
   PubMed Web of Science ®Google Scholar
• Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012;23(4):265–273. doi:10.3802/jgo.2012.23.4.265
   PubMed Web of Science ®Google Scholar